




VISMEDERI

ANALYSES FOR LIFE IMPROVEMENT



*We prove.
You improve.*

Content

I. Founder and Chief Scientific Officer	03
II. Company Profile	04
III. Vaccine Department	06
IV. Clinical / Pre-Clinical testing	08
V. Quality	10
VI. VisMederi America	12
VII. Project Management	14
VIII. Worldwide Business	15
IX. Research Projects	16
X. Human Resources	18
XI. VisMederi Group	20
XII. Synergies Partnerships	22
XIII. Economic and Financial Indicators	24
XIV. Scientific Publication	26

Founder and Chief Scientific Officer



**Emanuele Montomoli is the
founder and CSO of VisMederi Srl**

VisMederi Srl, the innovative Sienese Company established in June 2009 by the Department of Molecular Medicine of the University of Siena. Within a few years, the Company has integrated in the field of Life Sciences and Public Health, gaining the role of a highly qualified and reliable partner at an international level.

Emanuele Montomoli
Founder and Chief Scientific Officer of VisMederi

A handwritten signature in black ink, appearing to read 'Emanuele Montomoli'.

VisMederi offers its clients a large portfolio of qualified and serological assays for pre-clinical and clinical activities.

Page 08

VisMederi provides its clients with comprehensive clinical trial and research project support, from concept to completion, in compliance with the most stringent quality standards.

Page 14

Company Profile

VisMederi is a globally competent, well-resourced Research and Service Company that assists corporations and the pharmaceutical industry in enhancing public health through the development and optimization of safer and more efficient drugs and vaccines.

VisMederi's headquarters are located in Siena, Italy, a city with a research tradition extending back to the early 20th century, a center of international excellence in the field of vaccines and Life Sciences, and home to one of the most prestigious universities in Italy. VisMederi conducts and perfects serological tests to evaluate the immunogenicity of vaccines, creates and validates bioanalytical methods and experimental protocols for the release of therapeutic molecules and vaccines in development phases, and performs quality control at the intermediate stages of vaccine production thanks to the considerable scientific expertise and experience of its management and staff.

WHY VisMederi?

01.

**Competence,
skills and expertise**

02.

Quality

03.

Reliability

04.

**Flexibility, dynamism
and speed**



VisMederi Headquarter

Via Franco Ferrini 53
Loc. Tognazza
Monteriggioni
Siena - Italy



VisMederi Laboratories

Strada del Petriccio e
Belriguardo 35
Siena - Italy

Loc. Belvedere, ing. 2
Zona Industriale
53034 Colle Val d'Elsa
Siena - Italy



Vaccine Department

VisMederi constantly undergoes a validation process in accordance with EMA, FDA and PMDA international guidelines, in order to demonstrate the validity, the trustworthiness and robustness of its tests.

All of VisMederis activities are carried out in compliance with the European system of certification:

ISO 9001:2015

Quality Management System

ISO 27001

Information Security Management System and Cybersecurity

ISO 15189

QMS for Medical Laboratories

GCLP

Accreditation for Good Clinical Laboratory Practice

22

Laboratories (1500 mq)

Biological risk category

8 Biosafety Level 2

Laboratories

8 Biosafety Level 2 +

Laboratories

3 Biosafety Level 3

Laboratories

3 Cell Culture

Facilities



Embarking on a new chapter in innovation and scientific excellence: VisMederi proudly announces the cutting-edge lab facility. State-of-the-art structure spreads across an impressive 4000 square meters, fully equipped to propel us into the forefront of biomedical research.

2000

Square meters for Logistic and Sample Management

An extensive area, dedicated solely to ensuring the seamless workflow and safeguarding vital samples.



-20°C

-80°C

LIQUID
NITROGEN

Clinical Pre-Clinical testing





VisMederi offers its clients a large portfolio of qualified serological assays for pre-clinical and clinical activities

The tests conducted within VisMederi's facilities are routinely validated and standardized in order to assure high-quality protocols applicable in both clinical trial and research settings. All laboratory experiments are conducted in BSL2, BSL+, and BSL3 environments.

Traditional assays for the evaluation of virus vaccine immunogenicity characterize VisMederi's daily research, but in order to respond effectively

to the needs of current and potential partners, the company is continually optimizing and validating serological assays, with an emphasis on innovative platforms. Assays Development at VisMederi is responsible for the design, optimization, and standardization of bioanalytical microbiological, serological, and viral assays and tests related to vaccine immunogenicity evaluation and epidemiological screening.



RESPIRATORY VIRUSES

SEASONAL INFLUENZA, RSV, HMPV & PIV3

Live-virus Micro Neutralization Assay
Pseudotype-based Micro Neutralization Assay
HAI Hemagglutination Inhibition Assay
SRH Single Radial Hemolysis Assay
ELLA Anti-Neuraminidase Ab Assay
ELISA IgG/IgM/IgA
ELISpot
Intracellular Cytokine Staining FACS

AVIAN INFLUENZA HPAI & LPAI

HAI Hemagglutination Inhibition Assay
SRH Single Radial Hemolysis Assay
Live-virus Micro Neutralization Assay
Pseudotype-based Micro Neutralization Assay
ELLA Anti Neuraminidase Ab

SARS-COV-2 ASSAYS

ELISA IgA, IgM, IgG and Subclasses
ELISA Mucosal IgA
ELISA Avidity
Elecys Cobas S and N quantitative
Live Virus Neutralization CPE
Live Virus Neutralization PRNT
Lentiviral-Pseudotypes Neutralization Assay
VSV-Pseudotypes Neutralization Assay
Intracellular Cytokine Staining FACS
ELISpot
Viral Escape Assay

BACTERIAL Assays

Serum Bactericidal Assay (SBA/L-SBA)
Opsonophagocytic Assay (OPA)
Opsonophagocytic Killing Assay (OPKA)
Toxin Neutralization Assay
Whole Cell ELISA Assay
ELISA Assay
Luminex

MULTIPARAMETRIC PLATFORMS

Luminex Multiplex Assay
Mesoscale Platform (MSD)
CYTOF

EMERGING Viruses Assays

Nipah (Pseudovirus Neutralization & ELISA)
Yellow Fever 17D (HAI & PRNT)
Dengue (Neutralization & PRNT)
Zika (Neutralization & PRNT)
Monkeypox (Neutralization & ELISA)
Vaccinia (Neutralization & ELISA)
West Nile (Neutralization & PRNT)
Chikungunya (Neutralization & Pseudotypes Neut.)
Lassa (Pseudotypes Neutralization)
Ebola (Pseudotypes Neutralization)
Marburg (Pseudotypes Neutralization)
Rift Valley (Live-virus Neutralization)

Quality

VisMederi has made Quality one of its hallmarks highly recognized and appreciated by national and international customers

Continuous improvement, data integrity, attention to details and regulatory compliance are driving forces that envelope each internal process and combines together with an intense audit program and with a complete set of procedures to assure full compliance of regulatory standards and ISOs quality requirements.

Certifications and accreditations

VisMederi Group is recognised worldwide for its excellent certified services. Certifications are considered true quality indicators for customers and represent an effective stimulus for company growth.

Quality Management System

UNI EN ISO 9001:2015

Released by TUV Austria

VisMederi is UNI EN ISO 9001:2015 certified for its Quality Management System. Quality is defined by the ISO 9001:2015 as the level in which a series of intrinsic characteristics meet the requirements in a process of continual improvement.

Accreditation for Medical Laboratories

UNI EN ISO 15189:2024

Released by Accredia

VisMederi obtained Accredia's accreditation as a medical laboratory operating in compliance with UNI EN ISO 15189:2007. The standard specifies requirements concerning the quality and competences in terms of methodologies, scientific, technical and technological, organizational and procedural elements, as well as the specialization of the staff. The management system requirements of ISO 15189 naturally meet the principles of ISO 9001:2008 Quality Management System – Requirements.

Accreditation for Good Clinical Laboratory Practices (GCLP)

Good Clinical Laboratory Practices

Released by Qualogy

VisMederi is GCLP (Good Clinical Laboratory Practices) accredited by the external British independent company Qualogy. The accreditation certifies the compliance with international guidelines from WHO for analysis and management of samples from clinical trials.

IT Security Management System

UNI CEI EN ISO/IEC 27001:2024

Released by TUV Austria

EN ISO 27001:2013 is an international standard that provides the requirements of an Information Security Management System – ISMS. The Standard includes people, processes and IT systems by applying a risk-based approach. VisMederi obtained this prestigious certification in 2019 in order to meet the contractual requirements of important customers as well as to improve its skills on data and information security.

VisMederi America

VisMederi is pleased to announce the establishment of VisMederi America a new company based in Cleveland that marks a strategic milestone in the Group's expansion into the United States.

The new entity aims to strengthen VisMederi's international presence, consolidate scientific partnerships and broaden collaboration opportunities in pre-clinical testing and vaccine research.

VisMederi's founder, Emanuele Montomoli, has appointed Jennifer Price and Brian Price as Directors of the new company, bringing with them extensive expertise in biomedical research and the management of international scientific programs.

Supporting the connection between the Italian and U.S. operations, Elisa Mennitto and Alessandro Manenti will play a key role as the scientific and operational bridge between the two locations, ensuring continuity and a unified strategic direction. VisMederi America brings together scientific excellence, operational



experience and strategic development capability, with the goal of becoming a key player in pre-clinical testing — including Influenza, RSV, hMPV and SARS-CoV-2 — as well as a reliable partner for institutions, research centers and industry stakeholders. A central aim of the new company is to enhance the Group's ability to participate in U.S. public funding programs, thereby increasing opportunities for growth and innovation across its research activities.

The launch of VisMederi America represents an essential step in the Group's global strategy.

Pre-clinical immunization and challenge studies (BSL2+ and BSL3)

Pre-clinical serological assays:

- Enzyme Linked Immunosorbent Assay - ELISA
- Luminex
- Live-virus Neutralization assays (FLU, RSV, SARS-CoV-2, hMPV, MPOX and others)
- Emerging viruses Pseudotypes Neutralization Assays (Nipah, Chikungunia, Ebola, Marburg, Lassa, MERS and others)
- FLU HI
- FLU ELLA-NA
- PBMC isolation

Protein production and optimization

Partnering for US grants

Business Development


Project Management

VisMederi offers its clients full clinical trial and research project support from concept through completion based on high quality standards.

Our services include scientific, technical, and logistical support for experiment protocol design and evaluation, process monitoring, sample analysis, data elaboration, release of results, and reporting. A team with diverse and complementary expertise allows us to administer projects comprehensively in order to better interpret the requirements and company goals of our clients.

VisMederi's laboratories and research facilities allow for thorough examination of all phases I, II, III, and IV of clinical trial development. In addition, it partners with laboratories, research facilities, and international research centers to develop pre-clinical protocols.

Worldwide Business



Research Projects

PEDVAC-iNTS

The PEDVAC-iNTS project, funded for 4 years by the European Union, within the EDCTP2 - European & Developing Countries Clinical Trial Partnership 2 program, involves international experts from 7 institutions including academies, research institutes, small and medium-sized enterprises (SMEs) and non-profit organizations from Europe and Africa.

The research team, coordinated by the Sclavo Vaccines Association of Siena together with the University of Siena, will conduct a phase I / II paediatric study in Ghana, a country where the disease is endemic. The project also aims at strengthening international collaboration, including partners from African countries, to improve disease awareness in resource-limited endemic countries where the disease represents a significant public health burden.

FLUuniversal

Influenza has been a major global problem for centuries. Although vaccination can reduce a flu epidemic's health and economic consequences, current vaccines are far from perfect. Many research teams have been working worldwide to create an effective universal flu vaccine, spending hundreds of millions on research and development. Yet, until now, no breakthrough has been achieved.

The FLUuniversal consortium believes that FLUuniversal is not "yet another costly universal influenza project" but a real opportunity to create a genuine universal flu vaccine which will set the new gold standard for rapid and cost-efficient vaccine development. FLUuniversal builds on a vaccine technology that already has surmounted key hurdles of novel vaccines (demonstration of safety and robust immunogenicity in humans and manufacturability) and combines these advances with an immunisation strategy proven to drive the immune response to features of influenza viruses that are widely, if not universally, displayed. The FLUuniversal consortium aims to develop DeltaFLU as Universal Flu Vaccine that protects against all influenza virus strains.

Inno4Vac

Vaccines are a huge public health achievement, saving an estimated 2.5 million lives every year and protecting millions more from illness and disability. However, developing new vaccines is extremely time consuming, costly and risky; on average it takes over 10 years and costs more than EUR 800 million to bring a vaccine to the market. However, in recent years, researchers in academia and biotech companies have made huge strides in fields such as immunology, big data and artificial intelligence. These advances could potentially speed up the development of new vaccines and make the whole process more efficient.

The aim of Inno4Vac is to harness these advances and incorporate them into the vaccine industry. The project brings together experts in clinical research, immunology, microbiology, systems biology, mathematical models, and regulatory issues. This diverse team will focus on four key areas.

Two areas focus on *in silico* (i.e., computer-based) tools. The first area uses artificial intelligence, big data analysis and computational modelling to build an open access, cloud-based platform to develop vaccines and assess their efficacy *in silico*.

The second *in silico* area focuses on developing a modular computational platform to model the manufacture and stability testing of vaccines.

The other two areas focus on lab-based tools.

The first will develop new and improved models of certain diseases such as flu that can be used to study vaccine efficacy early in the development process. The other aims at delivering models based on human cells that offer a more reliable view of the level of immune protection a vaccine could offer.

Throughout the project, the partners will develop strategies and roadmaps to ensure that their models meet the needs of medicine regulators and integrate them into vaccine development processes. Ultimately, the models developed by the project should help to make vaccine development both faster and more efficient.

The logo for CEPI (Coalition for Epidemic Preparedness Initiatives) is displayed in a large, light blue, sans-serif font. The letters 'C', 'E', and 'P' are solid blue, while the 'I' is a lighter shade of blue. A small red dot is positioned above the 'I'.

VisMederi is part of CEPI's global laboratory network, supporting vaccine development and preparedness for emerging infectious diseases. During the COVID-19 pandemic, VisMederi was selected for CEPI's centralised laboratory network created to assess and compare immune responses to vaccine candidates using harmonised protocols. Today, VisMederi serves as a reference laboratory for influenza and Mpox vaccine programmes, contributing to CEPI's "enabling science" approach, which strengthens comparability through standardised assays, standards and reagents.

This work aligns with CEPI's 100 Days Mission to accelerate response timelines for future epidemic and pandemic threats.

INDIGO


Despite the availability of flu vaccines for several decades, influenza is still an important disease in both developing and developed countries with annual 500,000 casualties and many more diseased people. Vaccination is the most cost-effective way to control this disease. The aim of the INDIGO is to deliver 1) an affordable seasonal flu vaccine with high efficacy at low cost and possible exploitation within a few years after completion of the project and 2) a further improved flu vaccine concept dealing with technological shortcomings and challenges of wide-spread use.

People are the most important asset for VisMederi today and for its growth and development tomorrow. The success of VisMederi originates from the human capital investing its own skills and professionalism in this Company: strongly motivated women and men sharing the ideal of the Company, its steady rooting on the territory combined with its international perspective.




Human resources

The workgroup has been increased over the years by highly qualified technical professionals who have recognized VisMederi as a vibrant reality and an opportunity to test and broaden their knowledge. The Business departments collaborate with an Administration Department, a Finance and Management Control Department, a Legal Department, and a Communications Department to coordinate Research activities. Constant with a never-ending growth trend since the beginning of the business, VisMederi has continued to increase its human resources and to stabilize existing jobs, achieving excellence in a perspective of sharing its goals and preserving its values.





The growth of the staff from 2009 to 2026





VISMEDERI

— *Group* —



VISMEDERI
ANALYSES FOR LIFE IMPROVEMENT



VISMEDERI
HOLDING



VISMEDERI
DIAGNOSTICS



VISMEDERI
LIFE SCIENCES



fondazione
VISMEDERI

VISMEDERI HOLDING is the company that holds a qualified share of the companies that are part of the VisMederi Group. The Group operates in various business areas all related to Research and Innovation in the fields of Public Health, Life Sciences and Biotechnologies and is composed of VisMederi Srl, VisMederi Research Srl, VisMederi Life Sciences Srl, VisMederi Diagnostics, VisMederi Pharma Srl and ETHS Srl – Education and Training for Health Sciences Srl with single shareholder.

www.vismederiholding.com

VISMEDERI LIFE SCIENCES offers professional chemical-physical and microbiological analysis services within the scope of food and environmental self-control procedures through investigation on food, work surfaces, water and soil. It also carries out validation and drafting of HACCP self-control plans, training courses on current regulations, internal and supplier inspections and qualified consultancy.

Today the VisMederi Life Sciences laboratory is able to carry out tests for the detection of Coronavirus on different types of surfaces and in any structure, detecting the presence of SARS COV-2 virus RNA using a Real Time PCR technique.

www.vismederilifesciences.com

VISMEDERI DIAGNOSTICS is a private health care facility located in Siena, Italy. The diagnostic section laboratory is responsible for performing clinical tests for the prevention, diagnosis, and monitoring of diseases and infections.

Our goal at VisMederi Diagnostics is to provide citizens and businesses with fast and efficient testing services, using state-of-the-art equipment and specialized personnel. We are accredited and licensed by the Tuscany Region, ensuring that our services meet all necessary standards and regulations.

www.vismederidiagnostics.com



The **FONDAZIONE VISMEDERI** is a non-profit organization which exclusively works in the field of social solidarity, training and scientific research of particular social interest. It aims at improving the global health conditions of humanity by supporting and promoting the knowledge, development and production of new vaccines, especially against neglected diseases, accelerating their introduction for the benefit of the poorest populations and countries. The VisMederi Foundation promotes and encourages, also through the establishment of Research Centres, initiatives aimed at deepening and disseminating knowledge of these disciplines for the purposes of scientific, social, economic and cultural progress.

www.fondazionevismederi.org

Synergies Partnerships



UNIVERSITY OF SIENA

The synergy with the University of Siena has continued both within the framework of European projects and with the Molecular Epidemiology Research Laboratory directed by Prof. Emanuele Montomoli. Intense collaboration has continued with the Toscana Life Sciences incubator in Siena.

Collaborating to various research projects, the University of Siena is for VisMederi also an important think tank, in the form of PhD studies in business. The Company contributed to a PhD in Life Sciences funding supporting the project. Several researchers have carried out their PhD in VisMederi, helping to enrich the knowledge and skills of the Company. VisMederi has also contributed to various initiatives promoted by the University, from scientific dissemination activities to activities supporting active job search and introduction of high school students to the world of Sciences and Research.

VisMederi is also part of the Institute for Global Health that is the natural evolution of the University of Siena's tradition in science, infectious diseases, its prevention and treatment, vaccines and public health. The IFGH offers internationally recognized programs delivered by global academic and industry leaders in selected areas of global health, equipping program participants with the practical and professional expertise they need to lead the next generation of scientists, researchers, and health practitioners across the globe.





UNIVERSITÀ
DEGLI STUDI
DI MILANO

University of Milan

The partnership with the University of Milan started between the first and the second Italian wave of SARS-CoV-2 in 2020. Initially the collaboration was based on the development of new generation of purified proteins synthesized through the *Leishmania tarentolae* platform. Subsequently

the collaboration was strengthened through the development of a new potential mucosal vaccine that uses the *Leishmania* platform as a carrier for the immunological response. To date, the collaboration continues with several scientific publications in the field of infectious diseases prevention.



FONDAZIONE TOSCANA LIFE SCIENCES


VisMederi has set up its own laboratories in the Bioincubator and has collaborated in science projects promoted by the TLS Foundation with the aim to introduce people to the world of research, science, innovation and business culture.

Economic and Financial Indicators

2019/2024


RATIOS	2024	2023	2022	2021	2020
Net Sales	30.533.725	26.540.261	23.075.541	14.439.095	5.982.693
EBITDA / Net Sales	52,79%	51,94%	57,79%	40,56%	14,13%
EBIT	14.244.262	12.880.242	12.924.570	5.620.275	683.251
EBITDA	16.118.766	13.785.039	13.334.852	5.856.681	845.653
ROE	54,89%	62,58%	86,21%	89,88%	37,06%
ROI	30,35%	37,26%	52,24%	39,78%	10,82%
ROS	46,65%	48,53%	56,01%	39,82%	11,42%
ROA	65,49%	57,49%	90,02%	83,73%	16,53%
ROCE	39,86%	45,84%	73,86%	64,14%	24,73%
Capitalization rate	0,69	0,66	0,59	0,46	0,39
Operating Profit Margin Normal (OPM)	46,65%	48,53%	56,01%	38,92%	11,42%
Net Profit Margin (NPM)	35,13%	34,61%	39,54%	28,01%	9,11%
Debt Ratio	30,64%	33,94%	40,34%	53,84%	60,78%
Debt to Equity	0,44	0,51	0,69	1,19	1,55
Leverage	1,44	1,51	1,69	2,17	2,55
Total Solvency Ratio	3,38	2,95	2,45	1,82	1,65
Current Ratio	3,31	3,71	2,42	2,06	1,33
Acid Test	3,23	3,64	2,38	1,80	1,26

ROE
2024




2023 - 67,62%
2022 - 86,21%
2021 - 89,88%
2020 - 37,06%
2019 - 24,29%

ROI
2024



2023 - 37,14%
2022 - 52,64%
2021 - 39,78%
2020 - 10,82%
2019 - 11,09%


ROS
2024



2023 - 53,98%
2022 - 52,64%
2021 - 39,82%
2020 - 11,42%
2019 - 10,12%


2024

Net Sales: 30.533.725
EBIT: 14.244.262
EBITDA: 16.118.766



2023

Net Sales: 26.540.261
EBIT: 12.880.242
EBITDA: 13.785.039



Operating
Profit Margin
Normal
(OPM)

- » 46,65 % - 2024
- » 53,98 % - 2023
- » 56,01 % - 2022
- » 38,92 % - 2021
- » 11,42 % - 2020
- » 10,12 % - 2019

Scientific Publications

2020/2025

INFLUENZA

Obesity in adolescents does not influence early immune responses to influenza vaccination.

Kristinsdottir I, Haraldsson A, Brynjolfsson SF, Helgason T, Ludviksson BR, Giancchetti E, Razzano I, Montomoli E, Thors V. *Infect Dis (Lond)*. 2023 Jun;55(6):415-424. doi: 10.1080/23744235.2023.2195491. Epub 2023 Apr 6. PMID: 37021768

Surveillance of Influenza and Other Airborne Transmission Viruses during the 2021/2022 Season in Hospitalized Subjects in Tuscany, Italy.

Milano G, Capitani E, Camarri A, Bova G, Capecchi PL, Lazzeri G, Lipari D, Montomoli E, Manini I. *Vaccines (Basel)*. 2023 Mar 31;11(4):776. doi: 10.3390/vaccines11040776. PMID: 37112687

The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing.

Trombetta CM, Marchi S, Montomoli E. *Expert Rev Vaccines*. 2022 Sep;21(9):1233-1242. doi: 10.1080/14760584.2022.2085565. Epub 2022 Jun 9. PMID: 35678205

Detection of antibodies against influenza D virus in swine veterinarians in Italy in 2004.

Trombetta CM, Montomoli E, Di Bartolo I, Ostanello F, Chiapponi

C, Marchi S. *J Med Virol*. 2022 Jun;94(6):2855-2859. doi: 10.1002/jmv.27466. Epub 2021 Nov 27. PMID: 34811769

Influenza Viruses and Vaccines: The Role of Vaccine Effectiveness Studies for Evaluation of the Benefits of Influenza Vaccines.

Trombetta CM, Kistner O, Montomoli E, Viviani S, Marchi S. *Vaccines (Basel)*. 2022 May 1;10(5):714. doi: 10.3390/vaccines10050714. PMID: 35632470

Detection of antibodies against influenza D virus in swine veterinarians in Italy in 2004.

Trombetta CM, Montomoli E, Di Bartolo I, Ostanello F, Chiapponi C, Marchi S. *J Med Virol*. 2021 Nov 23. doi: 10.1002/jmv.27466. Online ahead of print. PMID: 34811769

Effect of Repeated Freeze-Thaw Cycles on Influenza Virus Antibodies.

Torelli A, Giancchetti E, Monti M, Piu P, Barneschi I, Bonifazi C, Coluccio R, Ganfini L, La Magra LM, Marconi S, Marzucchi G, Pace R, Palladino L, Biagi B, Montomoli E. *Vaccines (Basel)*. 2021 Mar 17;9(3):267. doi: 10.3390/vaccines9030267. PMID: 33802846

Correlation of Influenza B Haemagglutination Inhibitor, Single-Radial Haemolysis and Pseudotype-Based Microneu-

tralisation Assays for Immunogenicity Testing of Seasonal Vaccines.

Carnell GW, Trombetta CM, Ferrara F, Montomoli E, Temperton NJ. *Vaccines (Basel)*. 2021 Jan 28;9(2):100. doi: 10.3390/vaccines9020100. PMID: 33525543

Serologically-Based Evaluation of Cross-Protection Antibody Responses among Different A(H1N1) Influenza Strains.

Marchi S, Manini I, Kistner O, Piu P, Remarque EJ, Manenti A, Biuso F, Carli T, Lazzeri G, Montomoli E, Trombetta CM. *Vaccines (Basel)*. 2020 Nov 5;8(4):656. doi: 10.3390/vaccines8040656. PMID: 33167390

The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus.

Rajaram S, Wojcik R, Moore C, Ortiz de Lejarazu R, de Lusignan S, Montomoli E, Rossi A, Pérez-Rubio A, Trilla A, Baldo V, Jandhyala R, Kassianos G. *Vaccine*. 2020 Aug 27;38(38):6047-6056. doi: 10.1016/j.vaccine.2020.06.021. Epub 2020 Jun 26. PMID: 32600916

Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement.

Sicca F, Martinuzzi D, Montomoli E, Huckriede A. *Vaccine*. 2020 Mar 4;38(11):2527-2541. doi: 10.1016/j.vaccine.2020.01.088. Epub 2020 Feb 7. PMID: 32044163

Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine.

Manenti A, Maciola AK, Trombetta CM, Kistner O, Casa E, Hyseni I, Razzano I, Torelli A, Montomoli E. *Vaccines (Basel)*. 2020 Jan 24;8(1):43. doi: 10.3390/vaccines8010043. PMID: 31991681

SARS-COV-2

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees.

Dapporto F, Leonardi M, Trombetta CM, Semplici C, Piu P, Piccini G, Benincasa L, Marchi S, Andreano E, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A, Montomoli E. *Hum Vaccin Immunother*. 2022 Nov 30;18(6):2129196. doi: 10.1080/21645515.2022.2129196. Epub 2022 Oct 21. PMID: 36269939

A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?

Trombetta CM, Marchi S, Viviani S, Manenti A, Casa E, Dapporto F, Remarque EJ, Bollati V, Manini I, Lazzeri G, Montomoli E. *Hum Vaccin Immunother*. 2022 Nov 30;18(5):2047582. doi: 10.1080/21645515.2022.2047582. Epub 2022 Mar 15. PMID: 35289714

SARS-CoV-2 Seroconversion and Pregnancy Outcomes in a Population of Pregnant Women Recruited in Milan, Italy, between April 2020 and October 2020.

Accurti V, Gambitta B, Iodice S, Manenti A, Boito S, Dapporto F,

Leonardi M, Molesti E, Fabietti I, Montomoli E, Bollati V, Persico N. *Int J Environ Res Public Health*. 2022 Dec 13;19(24):16720. doi: 10.3390/ijerph192416720. PMID: 36554602

Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility.

Trombetta CM, Marchi S, Leonardi M, Stufano A, Lorusso E, Montomoli E, Decaro N, Buonvino N, Lovreglio P. *Hum Vaccin Immunother*. 2022 Dec 30;18(7):2153537. doi: 10.1080/21645515.2022.2153537. Epub 2022 Dec 12. PMID: 36503363

Surveillance of Severe Acute Respiratory Infection and Influenza Vaccine Effectiveness among Hospitalized Italian Adults, 2021/22 Season.

Panatto D, Domnich A, Chironna M, Loconsole D, Napoli C, Torsello A, Manini I, Montomoli E, Pariani E, Castaldi S, Orsi A, Icardi G, On Behalf Of The It-Bive-Hosp Network Study Group. *Vaccines (Basel)*. 2022 Dec 30;11(1):83. doi: 10.3390/vaccines11010083. PMID: 36679928

Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.

Trombetta CM, Marchi S, Leonardi M, Coppola C, Benincasa L, Marotta MG, Buonvino N, Maes P, Stufano A, Pontrelli D, Vasinioti VI, Manenti A, Camero M, Montomoli E, Decaro N, Lovreglio P. *Acta Trop*. 2023 Dec;248:107042. doi: 10.1016/j.actatropica.2023.107042. Epub 2023 Oct 18. PMID: 37863379

Lower frequency of SARS-CoV-2-associated severe respiratory infections among adults vaccinated against the 2021/22 season influenza.

Domnich A, Milano G, Capitani E, Camarri A, Bova G, Capecci PL, Montomoli E, Manini I. *Respir*

Med Res. 2023 Jun;83:100979. doi: 10.1016/j.resmer.2022.100979. Epub 2022 Nov 25. PMID: 36565562

Pyroptosis: A Promising Mechanism Linking SARS-CoV-2 Infection to Adverse Pregnancy Outcomes.

Monti P, Solazzo G, Accurti V, Gambitta B, Iodice S, Boito S, Cantone L, Manenti A, Dioni L, Montomoli E, Persico N, Bollati V. *Int J Mol Sci*. 2023 May 25;24(11):9278. doi: 10.3390/ijms24119278. PMID: 37298229

mRNA vaccines and hybrid immunity use different B cell germ lines against Omicron BA.4 and BA.5.

Andreano E, Paciello I, Pierleoni G, Maccari G, Antonelli G, Abbiento V, Pileri P, Benincasa L, Giglioli G, Piccini G, De Santi C, Sala C, Medini D, Montomoli E, Maes P, Rappuoli R. *Nat Commun*. 2023 Mar 28;14(1):1734. doi: 10.1038/s41467-023-37422-y. PMID: 36977711

SARS-CoV-2 epidemiological trend before vaccination era: a seroprevalence study in Apulia, Southern Italy, in 2020.

Marchi S, Coppola C, Piu P, Benincasa L, Dapporto F, Manenti A, Viviani S, Montomoli E, Trombetta CM. *Z Gesundh Wiss*. 2023 Feb 4:1-6. doi: 10.1007/s10389-023-01834-3. Online ahead of print. PMID: 36776202

B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response.

Andreano E, Paciello I, Pierleoni G, Piccini G, Abbiento V, Antonelli G, Pileri P, Manganaro N, Pantano E, Maccari G, Marchese S, Donnici L, Benincasa L, Giglioli G, Leonardi M, De Santi C, Fabbiani M, Rancan I, Tumbarello M, Montagnani F, Sala C, Medini D, De Francesco R, Montomoli E, Rappuoli R. *Nat Commun*. 2023 Jan 4;14(1):53. doi: 10.1038/s41467-022-35781-6. PMID: 36599850

In vitro virucidal activity of mouthwashes on SARS-CoV-2.

Buonavoglia A, Lanave G, Marchi S, Lorusso P, Montomoli E, Martella V, Camero M, Prati C, Trombetta CM. *Oral Dis.* 2022 Nov;28 Suppl 2:2509-2515. doi: 10.1111/odi.14205. Epub 2022 Apr 25. PMID: 35398970

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques.

Zabaleta N, Bhatt U, Héraré C, Maisonnasse P, Sanmiguel J, Diop C, Castore S, Estelien R, Li D, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Pascal Q, Naninck T, Kahlaoui N, Lemaître J, Relouzat F, Ronzitti G, Thibaut HJ, Montomoli E, Wilson JM, Le Grand R, Vandenberghe LH. *Mol Ther.* 2022 Sep 7;30(9):2952-2967. doi: 10.1016/j.ymthe.2022.05.007. Epub 2022 May 10. PMID: 35546782

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.

Trombetta CM, Piccini G, Pierleoni G, Leonardi M, Dapporto F, Marchi S, Andreano E, Paciello I, Benincasa L, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A, Montomoli E. *Commun Biol.* 2022 Sep 2;5(1):903. doi: 10.1038/s42003-022-03849-0. PMID: 36056181

Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.

Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N, Buonvino N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Molesti E, Trombetta CM, Manenti A, Montomoli E. *J Immunol Res.* 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022. PMID: 36093434

COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy.

Stufano A, Buonvino N, Trombetta CM, Pontrelli D, Marchi S, Lobefaro G, De Benedictis L, Lorusso E, Carofiglio MT, Vasin-ioti VI, Montomoli E, Decaro N, Lovreglio P. *Vaccines (Basel).* 2022 Jul 17;10(7):1137. doi: 10.3390/vaccines10071137. PMID: 35891301

Nasopharyngeal Bacterial Microbiota Composition and SARS-CoV-2 IgG Antibody Maintenance in Asymptomatic/Paucisymptomatic Subjects.

Ferrari L, Favero C, Solazzo G, Mariani J, Luginini A, Ferraroni M, Montomoli E, Milani GP, Bollati V. *Front Cell Infect Microbiol.* 2022 Jul 6;12:882302. doi: 10.3389/fcimb.2022.882302. eCollection 2022. PMID: 35873175

SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, Italy.

Marchi S, Lanave G, Camero M, Dapporto F, Manenti A, Benincasa L, Acciavatti A, Brogi G, Viviani S, Montomoli E, Trombetta CM. *Viruses.* 2022 Jun 30;14(7):1441. doi: 10.3390/v14071441. PMID: 35891420

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.

Andreano E, Paciello I, Marchese S, Donnici L, Pierleoni G, Piccini G, Manganaro N, Pantano E, Abbiento V, Pileri P, Benincasa L, Giglioli G, Leonardi M, Maes P, De Santi C, Sala C, Montomoli E, De Francesco R, Rappuoli R. *Nat Commun.* 2022 Jun 13;13(1):3375. doi: 10.1038/s41467-022-31115-8. PMID: 35697673

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.

Torres JL, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, Donnici L, Conti M, Planchais C, Planas D, Manganaro N, Pantano E, Paciello I, Pileri P, Bruel T, Montomoli E, Mouquet H, Schwartz O, Sala C, De Francesco R, Wilson IA, Rappuoli R, Ward AB. *Proc Natl Acad Sci U S A.* 2022 May 17;119(20):e2120976119. doi: 10.1073/pnas.2120976119. Epub 2022 May 12. PMID: 35549549

Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD004J08 after intramuscular injection.

Lanini S, Milleri S, Andreano E, Nosari S, Paciello I, Piccini G, Gentili A, Phogat A, Hyseni I, Leonardi M, Torelli A, Montomoli E, Paolini A, Frosini A, Antinori A, Nicastri E, Girardi E, Plazzi MM, Ippolito G, Vaia F, Della Cioppa G, Rappuoli R. *Nat Commun.* 2022 Apr 27;13(1):2263. doi: 10.1038/s41467-022-29909-x. PMID: 35477725

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose.

Mangia A, Serra N, Cocomazzi G, Giambra V, Antinucci S, Maiorana A, Giuliani F, Montomoli E, Cantaloni P, Manenti A, Piazzolla V. *Front Public Health.* 2022 Mar 31;10:847384. doi: 10.3389/fpubh.2022.847384. eCollection 2022. PMID: 35433614

Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects.

Giancchetti E, Cianchi V, Torelli A, Montomoli E. *Vaccines (Basel).* 2022 Feb 27;10(3):372. doi: 10.3390/vaccines10030372. PMID: 35335004

Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects.

Manenti A, Giancchetti E, Dapporto F, Leonardi M, Cantaloni

P, Fattorini F, Piu P, Bollati V, Pastorino U, Apolone G, Sozzi G, Montomoli E.
J Immunol Methods. 2022 Jan;500:113197. doi: 10.1016/j.jim.2021.113197. Epub 2021 Nov 26. PMID: 34843712

Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting.
Montomoli E, Apolone G, Manenti A, Boeri M, Suatoni P, Sabia F, Marchiani A, Bollati V, Pastorino U, Sozzi G.
Viruses. 2021 Dec 30;14(1):61. doi: 10.3390/v14010061. PMID: 35062265

Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.
Andreano E, Paciello I, Piccini G, Manganaro N, Pileri P, Hyseni I, Leonardi M, Pantano E, Abbiento V, Benincasa L, Giglioli G, De Santi C, Fabbiani M, Rancan I, Tumbarello M, Montagnani F, Sala C, Montomoli E, Rappuoli R.
Nature. 2021 Dec;600(7889):530-535. doi: 10.1038/s41586-021-04117-7. Epub 2021 Oct 20. PMID: 34670266

Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
Szymczak A, Jędruchiewicz N, Torelli A, Kaczmarzyk-Radka A, Coluccio R, Kłak M, Konieczny A, Ferenc S, Witkiewicz W, Montomoli E, Miernikiewicz P, Bąchor R, Dąbrowska K.
J Gen Virol. 2021 Nov;102(11):001692. doi: 10.1099/jgv.0.001692. PMID: 34816794

The theory and practice of the viral dose in neutralization assay: Insights on SARS-CoV-2 "doublethink" effect.
Manenti A, Molesti E, Maggetti M, Torelli A, Lapini G, Montomoli E.
J Virol Methods. 2021 Nov;297:114261. doi: 10.1016/j.jviromet.2021.114261. Epub 2021 Aug 14. PMID: 34403775

Reply to comments on: Unexpected detection of SARS-CoV-2 antibodies in the prepanemic period in Italy.
Sozzi G, Manenti A, Boeri M, Sabia F, Montomoli E, Pastorino U, Apolone G.
Tumori. 2021 Oct;107(5):472-473. doi: 10.1177/03008916211009688. Epub 2021 Apr 20. PMID: 33877026

Unexpected detection of SARS-CoV-2 antibodies in the prepanemic period in Italy.
Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, Mazzini L, Martinuzzi D, Cantone L, Milanese G, Sestini S, Suatoni P, Marchiani A, Bollati V, Sozzi G, Pastorino U. Tumori. 2021 Oct;107(5):446-451. doi: 10.1177/0300891620974755. Epub 2020 Nov 11. PMID: 33176598

Epidemiological and virological surveillance of Severe Acute Respiratory Infections in the 2019/2020 season in Siena, Tuscany, Italy.
Capitani E, Montomoli E, Camarri A, Bova G, Capecci PL, Mercone A, Nante N, Manini I.
J Prev Med Hyg. 2021 Sep 15;62(3):E782-E788. doi: 10.15167/2421-4248/jpmh2021.62.3.2297. eCollection 2021 Sep. PMID: 34909509

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, Dal Monego S, Pantano E, Manganaro N, Manenti A, Manna R, Casa E, Hyseni I, Benincasa L, Montomoli E, Amaro RE, McLellan JS, Rappuoli R.
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):e2103154118. doi: 10.1073/pnas.2103154118. PMID: 34417349

Evaluation of the automated LIAISON® SARS-CoV-2 Trimeric IgG assay for the detection of circulating antibodies.
Bonelli F, Blocki FA, Bunnell T,

Chu E, De La O A, Grenache DG, Marzocchi G, Montomoli E, Okoye L, Pallavicini L, Strevia VA, Torelli A, Wagner A, Zanin D, Zierold C, Wassenberg JJ.
Clin Chem Lab Med. 2021 Mar 15;59(8):1463-1467. doi: 10.1515/cclm-2021-0023. Print 2021 Jul 27. PMID: 33711225

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.
Trombetta CM, Marchi S, Viviani S, Manenti A, Benincasa L, Ruello A, Bombardieri E, Vicenti I, Zazzi M, Montomoli E.
Viruses. 2021 Jul 12;13(7):1347. doi: 10.3390/v13071347. PMID: 34372553

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Mazzini L, Martinuzzi D, Hyseni I, Benincasa L, Molesti E, Casa E, Lapini G, Piu P, Trombetta CM, Marchi S, Razzano I, Manenti A, Montomoli E.
J Immunol Methods. 2021 Feb;489:112937. doi: 10.1016/j.jim.2020.112937. Epub 2020 Nov 28. PMID: 33253698

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma.
Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, Dal Monego S, Pantano E, Manganaro N, Manenti A, Manna R, Casa E, Hyseni I, Benincasa L, Montomoli E, Amaro RE, McLellan JS, Rappuoli R.
bioRxiv. 2020 Dec 28;2020.12.28.424451. doi: 10.1101/2020.12.28.424451. Preprint. PMID: 33398278

Serological follow-up of SARS-CoV-2 asymptomatic subjects.
Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, Bonzini M, Montomoli E, Bollati V; UNICORN Consortium.
Sci Rep. 2020 Nov 18;10(1):20048.

doi: 10.1038/s41598-020-77125-8.
PMID: 33208819

A review of COVID-19 vaccines in development: 6 months into the pandemic.

Sanicas M, Sanicas M, Diop D, Montomoli E.
Pan Afr Med J. 2020 Oct 5;37:124. doi: 10.11604/pamj.2020.37.124.24973. eCollection 2020. PMID: 33425157. Review.

Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.

Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, Marchi S, Montomoli E.
J Med Virol. 2020 Oct;92(10):2096-2104. doi: 10.1002/jmv.25986. Epub 2020 May 17. PMID: 32383254

Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays.

Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton NJ, Manenti A, Montomoli E. Viruses. 2020 Sep 10;12(9):1011. doi: 10.3390/v12091011. PMID: 32927639

SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy.

Milani GP, Montomoli E; UNICORN Consortium investigators, Bollati V, Alberti B, Bandi C, Bellini T, Bonzini M, Buscaglia M, Cantarella C, Cantone L, Carugno M, Casartelli S, Cavaletti G, D'Alessandro S, De Chiara F, Delbue S, Dioni L, Eberini I, Favero C, Ferrari L, Ferraroni M, Galastri L, Galli C, Hoxha M, Iodice S, La Vecchia C, Macchi C, Manini I, Marchi S, Mariani J, Pariani E, Pesatori AC, Rota F, Ruscica M, Schioppo T, Tarantini L, Trombetta CM, Valsecchi MG, Vicenzi M, Zanchetta G.
Eur J Intern Med. 2020

Aug;78:161-163. doi: 10.1016/j.ejim.2020.06.010. Epub 2020 Jun 9. PMID: 32564906

Moderate Vaccine Effectiveness against Severe Acute Respiratory Infection Caused by A(H1N1) pdm09 Influenza Virus and No Effectiveness against A(H3N2) Influenza Virus in the 2018/2019 Season in Italy.

Rizzo C, Gesualdo F, Loconsole D, Pandolfi E, Bella A, Orsi A, Guarona G, Panatto D, Icardi G, Napoli C, Orsi GB, Manini I, Montomoli E, Campagna I, Russo L, Alfonsi V, Puzelli S, Reale A, Raucci U, Piccioni L, Concato C, Ciofi Degli Atti ML, Villani A, Chironna M, Tozzi AE. Vaccines (Basel). 2020 Jul 30;8(3):427. doi: 10.3390/vaccines8030427. PMID: 32751584

MONKEYPOX

A. Correlation between micro-neutralization test and a multiplexed immunoassay for evaluation of monkeypox and vaccinia virus antibodies before and after smallpox vaccination.

Alvaro A, Cattaneo GM, Varotto-Bocazzi I, Molteni R, Mendoza-Roldan JA, Brilli M, Conconi MS, Giovagnoli V, Manenti A, Otranto D, Bandi C, Epis S. Parasit Vectors. 2025 Jul 1;18(1):243. doi: 10.1186/s13071-025-06871-3. PMID: 40598545; PMCID: PMC12210423.

Evaluation of monkeypox- and vaccinia-virus neutralizing antibodies before and after smallpox vaccination: A sero-epidemiological study. J Med Virol.

Marchi S, Piccini G, Cantaloni P, Guerrini N, Zannella R, Coluccio R, Benincasa L, Solfanelli N, Remarque EJ, Viviani S, Kistner O, Temperton N, Montomoli E, Manenti A, Trombetta CM. 2024 Jun;96(6):e29728. doi: 10.1002/jmv.29728. PMID: 38860589.

Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples

after vaccination and natural infection.

Manenti A, Solfanelli N, Cantaloni P, Mazzini L, Leonardi M, Benincasa L, Piccini G, Marchi S, Boncioli M, Spertilli Raffaelli C, Tacconi D, Mattiuzzo G, Kistner O, Montomoli E, Trombetta CM. Front Public Health. 2023 Jun 21;11:1195674. doi: 10.3389/fpubh.2023.1195674. eCollection 2023. PMID: 37415699

RSV

Establishment and validation of a high-throughput micro-neutralization assay for respiratory syncytial virus (subtypes A and B).

Bonifazi C, Trombetta CM, Barneschi I, Latanza S, Leopoldi S, Benincasa L, Leonardi M, Semplici C, Piu P, Marchi S, Montomoli E, Manenti AJ Med Virol. 2023 Jul;95(7):e28923. doi: 10.1002/jmv.28923. PMID: 37403896

FLAVIVIRUS

A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine.

Desai S, Anil K, Potey AV, Sindhu Y, Grappi S, Lapini G, Manney S, Tyagi P, Montomoli E, Poonawalla CS, Kulkarni PS. NPJ Vaccines. 2022 Dec 19;7(1):170. doi: 10.1038/s41541-022-00595-6. PMID: 36535976

Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage.

Marchi S, Dragoni F, Boccutto A, Idoko OT, Zazzi M, Sow S, Diallo A, Viviani S, Montomoli E, Vicenti I, Trombetta CM. Acta Trop. 2023 Jan;237:106736. doi: 10.1016/j.actatropica.2022.106736. Epub 2022 Oct 29. PMID: 36374844

West Nile Virus Seroprevalence in the Italian Tuscany Region from 2016 to 2019.

Marchi S, Montomoli E, Viviani S, Giannechini S, Stincarelli MA, Lanave G, Camero M, Alessio C, Coluccio R, Trombetta CM. Pathogens. 2021 Jul 5;10(7):844.

doi: 10.3390/pathogens10070844.
PMID: 34357994

Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.

Marchi S, Viviani S, Remarque EJ, Ruello A, Bombardieri E, Bollati V, Milani GP, Manenti A, Lapini G, Rebuffat A, Montomoli E, Trombetta CM.
PLoS One. 2021 Jul 2;16(7):e0253977. doi: 10.1371/journal.pone.0253977. eCollection 2021. PMID: 34214116

Surveillance for Severe Acute Respiratory Infections among Hospitalized Subjects from 2015/2016 to 2019/2020 Seasons in Tuscany, Italy.

Manini I, Camarri A, Marchi S, Trombetta CM, Vicenti I, Dragoni F, Lazzeri G, Bova G, Montomoli E, Capecci PL.
Int J Environ Res Public Health. 2021 Apr 7;18(8):3875. doi: 10.3390/ijerph18083875. PMID: 33917106

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.

Andreano E, Nicastrì E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, Vacca F, Cardamone D, De Santi C, Torres JL, Ozorowski G, Benincasa L, Jang H, Di Genova C, Depau L, Brunetti J, Agrati C, Capobianchi MR, Castilletti C, Emiliozzi A, Fabbiani M, Montagnani F, Bracci L, Sautto G, Ross TM, Montomoli E, Temperton N, Ward AB, Sala C, Ippolito G, Rappuoli R.
Cell. 2021 Apr 1;184(7):1821-1835.e16. doi: 10.1016/j.cell.2021.02.035. Epub 2021 Feb 23. PMID: 33667349

Detection of IgM, IgG and SARS-CoV-2 RNA among the personnel of the University of Milan, March through May 2020: the UNICORN study.

Milani GP, Rota F, Favero C, Dioni L, Manenti A, Hoxha M, Pariani E, Albeti B, Pesatori AC, Montomoli

E, Bollati V; UNICORN Consortium investigators.
BMJ Open. 2021 Mar 24;11(3):e046800. doi: 10.1136/bmjopen-2020-046800. PMID: 33762247

Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012.

Marchi S, Viviani S, Montomoli E, Tang Y, Boccuto A, Vicenti I, Zazzi M, Sow S, Diallo A, Idoko OT, Bhat N, Trombetta CM.
Viruses. 2020 Jun 13;12(6):641. doi: 10.3390/v12060641. PMID: 32545775

BACTERIA

Current challenges and improvements in assessing the immunogenicity of bacterial vaccines.

Fantoni G, Boccadifuoco G, Verdiorosa F, Molesti E, Manenti A, Montomoli E. Front Microbiol. 2024 Jul 9;15:1404637. doi: 10.3389/fmicb.2024.1404637. PMID: 39044946; PMCID: PMC11263209.

Characterization of Enzyme-Linked Immunosorbent Assay (ELISA) for Quantification of Antibodies against Salmonella Typhimurium and Salmonella Enteritidis O-Antigens in Human Sera.

Aruta MG, Lari E, De Simone D, Semplici B, Semplici C, Dale H, Chirwa E, Kadwala I, Mbewe M, Banda H, Iturriza-Gomara M, Gordon M, Nyirenda T, Piu P, Pizzo M, Berlanda Scorza F, Grappi S, Canals R, Rossi O, On Behalf Of The Vacc-INTS Consortium Collaborators. BioTech (Basel). 2023 Aug 11;12(3):54. doi: 10.3390/biotech12030054. PMID: 37606441

Pathogenic signature of invasive non-typhoidal Salmonella in Africa: implications for vaccine development.

Piccini G, Montomoli E.
Hum Vaccin Immunother. 2020 Sep 1;16(9):2056-2071. doi: 10.1080/21645515.2020.1785791.

Epub 2020 Jul 21. PMID: 32692622. Review.

CFI

Validation of a double-color ELISpot assay of IFN-γ and IL-4 production in human peripheral blood mononuclear cells.

Dapporto F, De Tommaso D, Marrocco C, Piu P, Semplici C, Fantoni G, Ferrigno I, Piccini G, Monti M, Vanni F, Razzano I, Manini I, Montomoli E, Manenti AJ. Immunol Methods. 2024 Jan;524:113588. doi: 10.1016/j.jim.2023.113588. Epub 2023 Nov 29. PMID: 38040193

Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-γ Enzyme-Linked ImmunoSpot (ELISpot) protocols.

Waerlop G, Leroux-Roels G, Pagnon A, Begue S, Salaun B, Janssens M, Medagliani D, Pettini E, Montomoli E, Giancchetti E, Lambe T, Godfrey L, Bull M, Bellamy D, Amdam H, Bredholt G, Cox RJ, Clement FJ. Immunol Methods. 2023 Dec;523:113584. doi: 10.1016/j.jim.2023.113584. Epub 2023 Oct 31. PMID: 37918618

Flow cytometry as an integrative method for the evaluation of vaccine immunogenicity: A validation approach.

Giancchetti E, Torelli A, Piu P, Bonifazi C, Ganfani L, Montomoli E. Biochem Biophys Rep. 2023 Apr 22;34:101472. doi: 10.1016/j.bbrep.2023.101472. eCollection 2023 Jul. PMID: 37153861

VACCINES AND CLINICAL

PRECLINICAL STUDIES

Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized

with different vaccine platforms: A phase II/III, randomized clinical trial. *Vaccine*. 2025

Perez Marc G, Coria LM, Ceballos A, Rodríguez JM, Lombardo ME, Bruno L, Páez Córdoba F, Fascetto Cassero CG, Salvatori M, Rios Medrano M, Fulgenzi F, Alzogaray MF, Mykietiuik A, Uriarte IL, Itcovici N, Smith Casabella T, Corral G, Bruno M, Roldán O, Núñez SA, Cahn F, Yerino GA, Bianchi A, Braem V, Christmann A, Corradetti S, Darraidou MC, Di Nunzio L, Estrada T, López Castelo R, Marchionatti C, Pitocco L, Trias Uriarte V, Wood C, Zadoff R, Bues F, Garrido RM, Montomoli E, Manenti A; Laboratorio Pablo Cassará group for ARVAC; Demaría A, Prado L, Pueblas Castro C, Saposnik L, Geffner J, Montes de Oca F, Vega JC, Fló J, Bonvehí P, Cassará J, Pasquevich KA, Cassataro J. Epub 2025 Apr 3. PMID: 40179522.

Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity.

Bruno LA, Pueblas Castro C, Demaría A, Prado L, Fascetto Cassero CG, Saposnik LM, Páez Córdoba F, Rodríguez JM, Piccini G, Antonelli R, Lapini G, Temper-ton N, Del Priore SA, Hernando Insua AC, Kaufmann IG, Vega JC, Flo JM, Pasquevich KA, Coria LM, Cassataro J. NPJ Vaccines. 2025 May 29;10(1):108. doi: 10.1038/s41541-025-01156-3. PMID: 40442110; PMCID: PMC12122808.

Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19.

Epis S, Varotto-Boccazzi I, Manenti A, Rubolini D, Gabrieli P, Cattaneo GM, Gourlay L, Dapporto F, Monti M, Razzano I, Leonardi M, Iannaccone M, Recordati C, Bertola L, Fiorina P, Marvasi L, Montomoli E, Zuccotti G, Bandi C. Pharmacol Res. 2022 Dec;186:106546. doi: 10.1016/j.phrs.2022.106546. Epub

2022 Nov 4. PMID: 36336215

Adequate immune responses to vaccines after chemotherapy for leukaemia diagnosed in childhood.

Óskarsson Ý, Thors V, Vias RD, Lúðvíksson BR, Brynjólfsson SF, Giancchetti E, Razzano I, Montomoli E, Gísli Jónsson Ó, Haraldsson Á. Acta Paediatr. 2023 Dec 23. doi: 10.1111/apa.17070. Online ahead of print. PMID: 38140806

The burden of influenza and the role of influenza vaccination in adults aged 50-64 years: A summary of available evidence.

Marchi S, Fallani E, Salvatore M, Montomoli E, Trombetta CM. Hum Vaccin Immunother. 2023 Aug;19(2):2257048. doi: 10.1080/21645515.2023.2257048. Epub 2023 Oct 1. PMID: 37778401

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.

Palmer CD, Scallan CD, Kraemer Tardif LD, Kachura MA, Rappaport AR, Koralek DO, Uriel A, Gitlin L, Klein J, Davis MJ, Venkatraman H, Hart MG, Jaroslavsky JR, Kounlavouth S, Marrali M, Nganje CN, Bae K, Yan T, Leodones K, Egorova M, Hong SJ, Kuan J, Grappi S, Garbes P, Jooss K, Ustianowski A.

Nat Commun. 2023 Jun 6;14(1):3274. doi: 10.1038/s41467-023-39053-9. PMID: 37280238

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19.

Aurisicchio L, Brambilla N, Cazaniga ME, Bonfanti P, Milleri S, Ascierto PA, Capici S, Vitalini C, Girolami F, Giacovelli G, Caselli G, Visintin M, Fanti F, Ghirri M, Conforti A, Compagnone M, Lione L, Salvatori E, Pinto E, Muzi A, Marra E, Palombo F, Roscilli G, Manenti A, Montomoli E, Cadossi

M, Rovati LC. Mol Ther. 2023 Mar 1;31(3):788-800. doi: 10.1016/j.ymthe.2022.12.017. Epub 2022 Dec 27. PMID: 36575794

Rectal Administration of Leishmania Cells Elicits a Specific, Th1-Associated IgG2a Response in Mice: New Perspectives for Mucosal Vaccination against Leishmaniasis, after the Repurposing of a Study on an Anti-Viral Vaccine Candidate.

Varotto-Boccazzi I, Epis S, Cattaneo GM, Guerrini N, Manenti A, Rubolini D, Gabrieli P, Otranto D, Zuccotti G, Montomoli E, Bandi C. Trop Med Infect Dis. 2023 Aug 9;8(8):406. doi: 10.3390/tropicalmed8080406. PMID: 37624344

Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform.

Stuurman AL, Carmona A, Bicler J, Descamps A, Levi M, Baum U, Mira-Iglesias A, Bellino S, Hoang U, de Lusignan S, Bonaiuti R, Lina B, Rizzo C, Nohynek H, Díez-Domingo J; DRIVE Study Contributors. Front Public Health. 2023 Jul 20;11:1195409. doi: 10.3389/fpubh.2023.1195409. eCollection 2023. PMID: 37546295

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children.

Kazmin D, Clutterbuck EA, Napolitani G, Wilkins AL, Tarlton A, Thompson AJ, Montomoli E, Lapini G, Bihari S, White R, Jones C, Snape MD, Galal U, Yu LM, Rappuoli R, Del Giudice G, Pollard AJ, Pulendran B. NPJ Vaccines. 2023 Jul 13;8(1):100. doi: 10.1038/s41541-023-00702-1. PMID: 37443176

Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniasis and viral infections.

Bandi C, Mendoza-Roldan

JA, Otranto D, Alvaro A, Louzada-Flores VN, Pajoro M, Varotto-Boccazzi I, Brilli M, Manenti A, Montomoli E, Zuccotti G, Epis S. *Parasit Vectors*. 2023 Jan 26;16(1):35. doi: 10.1186/s13071-023-05651-1. PMID: 36703216

Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.

Rothen DA, Krenger PS, Nonic A, Balke I, Vogt AS, Chang X, Manenti A, Vedovi F, Resevisa G, Walton SM, Zeltins A, Montomoli E, Vogel M, Bachmann MF, Mohsen MO. *Allergy*. 2022 Aug;77(8):2446-2458. doi: 10.1111/all.15311. Epub 2022 Apr 15. PMID: 35403221

Leishmania tarentolae as an Antigen Delivery Platform: Dendritic Cell Maturation after Infection with a Clone Engineered to Express the SARS-CoV-2 Spike Protein.

Varotto-Boccazzi I, Garziano M, Cattaneo GM, Bisaglia B, Gabrieli P, Biasin M, Manenti A, Rubolini D, Clerici M, Montomoli E, Zuccotti GV, Trabattori D, Epis S, Bandi C. *Vaccines (Basel)*. 2022 May 19;10(5):803. doi: 10.3390/vaccines10050803. PMID: 35632559

Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.

Esposito S, Nauta J, Lapini G, Montomoli E, van de Witte S. *Vaccine*. 2022 Mar 18;S0264-410X(22)00263-8. doi: 10.1016/j.vaccine.2022.02.088. PMID: 35315323

Epidemic Preparedness-Leishmania tarentolae as an Easy-to-Handle Tool to Produce Antigens for Viral Diagnosis: Application to COVID-19.

Varotto-Boccazzi I, Manenti A, Dapporto F, Gourlay LJ, Bisaglia B, Gabrieli P, Forneris F, Faravelli S, Bollati V, Rubolini D, Zuccotti G, Montomoli E, Epis S, Bandi C.

Front Microbiol. 2021 Dec 13;12:736530. doi: 10.3389/fmicb.2021.736530. eCollection 2021. PMID: 34966362

Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes-Systematic Literature Review and Expert Consensus.

Ortiz de Lejarazu-Leonardo R, Montomoli E, Wojcik R, Christopher S, Mosnier A, Pariani E, Trilla Garcia A, Fickenscher H, Gärtner BC, Jandhyala R, Zambon M, Moore C. *Vaccines (Basel)*. 2021 Oct 29;9(11):1255. doi: 10.3390/vaccines9111255. PMID: 34835186. Review.

Progress on Seasonal and Pandemic Influenza Vaccines.

Trombetta CM, Montomoli E. *Vaccines (Basel)*. 2021 Sep 24;9(10):1068. doi: 10.3390/vaccines9101068. PMID: 34696176

Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.

Vesikari T, Nauta J, Lapini G, Montomoli E, van de Witte S. *Int J Infect Dis*. 2020 Mar;92:29-37. doi: 10.1016/j.ijid.2019.12.010. Epub 2019 Dec 12. PMID: 31838217 Clinical Trial.

A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).

Duong TN, Thiem VD, Anh DD, Cuong NP, Thang TC, Huong VM, Chien VC, Phuong NTL, Montomoli E, Holt R, Scorza FB, Flores J, Tewari T. *Vaccine*. 2020 Feb 5;38(6):1541-1550. doi: 10.1016/j.vaccine.2019.11.059. Epub 2019 Dec 4. PMID: 31812464 Clinical Trial.

COLLABORATIVE STUDIES

Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium.

Crossen VM, Moreira PCL, Engelhardt OG, Samolej J, Groeneveld GH, Jochems SP, Huisman W, Pedersen GK, Wörzner K, Recek L, Piccini G, Trombetta CM, Aspelund A, Hoag A, Reiter M, Wick C, Muster T, Kamerling. *Front Immunol*. 2025 May 23;16:1568778. doi: 10.3389/fimmu.2025.1568778. PMID: 40486504; PMCID: PMC12141322.

Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.

Manak M, Gagnon L, Phay-Tran S, Levesque-Damphousse P, Fabie A, Daugan M, Khan ST, Proud P, Hussey B, Knott D, Charlton S, Hallis B, Medigeshi GK, Garg N, Anantharaj A, Raqib R, Sarker P, Alam MM, Rahman M, Murreddu M, Balgobind A, Hofman R, Grappi S, Coluccio R, Calandro P, Montomoli E, Mattiuzzo G, Prior S, Le Duff Y, Page M, Mitchell J, Schwartz LM, Bartsch YC, Azizi A, Bernasconi V; CEPI CLN Study Group. *Lancet Microbe*. 2024 Jan 23:S2666-5247(23)00324-5. doi: 10.1016/S2666-5247(23)00324-5.

Development of a composite scoring system to rank communities at high risk of zero-dose children in Cameroon: A geospatial analysis.

Saidu Y, Agbor VN, Di Mattei P, Nchinjoh SC, Edwidge NN, Njoh AA, Muteh NJ, Prescott M, Wiwa O, Diack D, Flegere J, Montomoli E, Costa Clemens SA, Clemens RJ. *Glob Health*. 2023 Nov 17;13:04136. doi: 10.7189/jogh.13.04136. PMID: 37971948

The faces behind vaccination: unpacking the attitudes, knowl-

edge, and practices of staff of Cameroon's Expanded program on Immunization.

Saidu Y, Gu J, Ngege BM, Nchinjoh SC, Adidja A, Nnang NE, Muteh NJ, Zambou VM, Mbanga CM, Agbor VN, Ousmane D, Njoh AA, Flegere J, Diack D, Wiwa O, Montomoli E, Clemens SAC, Clemens R. *Hum Resour Health*. 2023 Nov 13;21(1):88. doi: 10.1186/s12960-023-00869-7. PMID: 37957695

Regional and sex inequalities of avoidable mortality in Italy: A time trend analysis.

Golinelli D, Guarducci G, Sanna A, Lenzi J, Sanmarchi F, Fantini MP, Montomoli E, Nante N. *Public Health Pract (Oxf)*. 2023 Oct 26;6:100449. doi: 10.1016/j.puhip.2023.100449. eCollection 2023 Dec. PMID: 38028252

Assessment of immunization data management practices in Cameroon: unveiling potential barriers to immunization data quality.

Saidu Y, Gu J, Ngege BM, Nchinjoh SC, Adidja A, Nnang NE, Muteh NJ, Zambou VM, Mbanga C, Agbor VN, Ousmane D, Njoh AA, Flegere J, Diack D, Wiwa O, Montomoli E, Clemens SAC, Clemens R. *BMC Health Serv Res*. 2023 Sep 27;23(1):1033. doi: 10.1186/s12913-023-09965-9. PMID: 37759205

Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?

Milano G, Guarducci G, Nante N, Montomoli E, Manini I. *Vaccines (Basel)*. 2023 Jun 4;11(6):1060. doi: 10.3390/vaccines11061060. PMID: 37376449

Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study.

Waldock J, Remarque EJ, Zheng B, Ho S, Hoschler K, Neumann B, Sediri-Schön H, Trombetta CM,

Montomoli E, Marchi S, Lapini G, Zhou F, Lartey SL, Cox RJ, Facchini M, Castrucci MR, Friel D, Ollinger T, Caillet C, Music N, Palladino G, Engelhardt OG; FLUCOP consortium. *Front Immunol*. 2023 Apr 18;14:1155552. doi: 10.3389/fimmu.2023.1155552. eCollection 2023. PMID: 37143658

The Hidden Impact of the COVID-19 Pandemic on Routine Childhood Immunization Coverage in Cameroon.

Saidu Y, Di Mattei P, Nchinjoh SC, Edwige NN, Nsah B, Muteh NJ, Ndoula ST, Abdullahi R, Zamir CS, Njoh AA, Adidja A, Ndiaye S, Wiwa O, Montomoli E, Clemens SAC. *Vaccines (Basel)*. 2023 Mar 14;11(3):645. doi: 10.3390/vaccines11030645. PMID: 36992229

An external quality assessment feasibility study: cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study.

Waldock J, Weiss CD, Wang W, Levine MZ, Jefferson SN, Ho S, Hoschler K, Londt BZ, Masat E, Carolan L, Sánchez-Ovando S, Fox A, Watanabe S, Akimoto M, Sato A, Kishida N, Buys A, Maake L, Fourie C, Caillet C, Raynaud S, Webby RJ, DeBeauchamp J, Cox RJ, Lartey SL, Trombetta CM, Marchi S, Montomoli E, Sanz-Muñoz I, Eiros JM, Sánchez-Martínez J, Duijsings D, Engelhardt OG. *Front Immunol*. 2023 Feb 28;14:1129765. doi: 10.3389/fimmu.2023.1129765. eCollection 2023. PMID: 36926342

Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium.

Begue S, Waerlop G, Salaun B, Janssens M, Bellamy D, Cox RJ, Davies R, Giancchetti E, Medaglini D, Montomoli E, Pettini E, Leroux-Roels G, Clement F, Pagnon A. *Front Immunol*. 2022 Oct 20;13:982887. doi: 10.3389/fimmu.2022.982887. eCollection 2022. PMID: 36341380

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.

Waerlop G, Leroux-Roels G, Lambe T, Bellamy D, Medaglini D, Pettini E, Cox RJ, Trieu MC, Davies R, Bredholt G, Montomoli E, Giancchetti E, Clement F. *Front Immunol*. 2022 Sep 8;13:984642. doi: 10.3389/fimmu.2022.984642. eCollection 2022. PMID: 36159843

Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study.

Bernard MC, Waldock J, Commandeur S, Strauß L, Trombetta CM, Marchi S, Zhou F, van de Witte S, van Amsterdam P, Ho S, Hoschler K, Lugovtsov V, Weir JP, Montomoli E, Cox RJ, Engelhardt OG, Friel D, Wagner R, Ollinger T, Germain S, Sediri-Schön H. *Front Immunol*. 2022 Jun 17;13:909297. doi: 10.3389/fimmu.2022.909297. eCollection 2022. PMID: 35784305

Immunity to measles in Italian children and adolescents: a persistent problem in view of measles elimination.

Marchi S, Monti M, Viviani S, Remarque EJ, Esposito S, Principi N, Ruggiero L, Montomoli E, Trombetta CM. *J Public Health (Oxf)*. 2021 Dec 10;43(4):e601-e609. doi: 10.1093/pubmed/fdaa153. PMID: 32915205

System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.

Vicenti I, Martina MG, Boccuto A,

De Angelis M, Giavarini G, Dragoni F, Marchi S, Trombetta CM, Cre-span E, Maga G, Eydoux C, Decroly E, Montomoli E, Nencioni L, Zazzi M, Radi M.
Eur J Med Chem. 2021 Nov 15;224:113683. doi: 10.1016/j.ej-mech.2021.113683. Epub 2021 Jul 5. PMID: 34273661

Measles immunity over two decades in two large Italian Regions: How far is the elimination goal?

Marchi S, Remarque EJ, Viviani S, Rizzo C, Monteverde Spencer GT, Coluccio R, Montomoli E, Trombetta CM.
Vaccine. 2021 Sep 24;39(40):5928-5933. doi: 10.1016/j.vaccine.2021.08.001. Epub 2021 Aug 26. PMID: 34456073

Seroprevalence of antibodies to cytomegalovirus in pregnant women in the Apulia region (Italy).

Trombetta CM, Viviani S, Montomoli E, Marchi S.
J Prev Med Hyg. 2021 Jul 30;62(2):E372-E376. doi: 10.15167/2421-4248/jpmh2021.62.2.1800. eCollection 2021 Jun. PMID: 34604575

Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study.

Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W.
Vaccines (Basel). 2021 Feb 17;9(2):166. doi: 10.3390/vaccines9020166. PMID: 33671378

Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells.

Vicenti I, Dragoni F, Monti M, Trombetta CM, Giannini A, Boccuto A, Saladini F, Rossetti B, De Luca A, Ciabattini A, Pastore G, Medagliani D, Orofino G, Montomoli E, Zazzi M.
J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001499. PMID: 33048041

Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.

Carreño JM, McDonald JU, Hurst T, Rigsby P, Atkinson E, Charles L, Nachbagauer R, Behzadi MA, Strohmeier S, Coughlan L, Aydllo T, Brandenburg B, García-Sastre A, Kaszas K, Levine MZ, Manenti A, McDermott AB, Montomoli E, Muchene L, Narpala SR, Perera RAPM, Salisch NC, Valkenburg SA, Zhou F, Engelhardt OG, Krammer F.
Vaccines (Basel). 2020 Nov 9;8(4):666. doi: 10.3390/vaccines8040666. PMID: 33182279

Measles Susceptibility in Apulia: The Italian Mirror?

Marchi S, Viviani S, Montomoli E, Trombetta CM.
J Infect Dis. 2020 Sep 14;222(8):1414-1415. doi: 10.1093/infdis/jiaa212. PMID: 32343809

Seroprevalence of Hepatitis E Virus in Forestry Workers from Trentino-Alto Adige Region (Northern Italy).

Monini M, Ostanello F, Dominicis A, Tagliapietra V, Vaccari G, Rizzoli A, Trombetta CM, Montomoli E, Di Bartolo I. Pathogens. 2020 Jul 14;9(7):568. doi: 10.3390/pathogens9070568. PMID: 32674277

Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials.

Domnich A, Manini I, Panatto D, Calabrò GE, Montomoli E.
Vaccines (Basel). 2020 Jun 19;8(2):325. doi: 10.3390/vaccines8020325. PMID: 32575440

The enemy at home: leishmaniasis in the Mediterranean basin, Italy on the focus.

Giancchetti E, Montomoli E.
Expert Rev Anti Infect Ther. 2020 Jun;18(6):563-577. doi: 10.1080/14787210.2020.1751611. Epub 2020 Apr 17. PMID: 32249634 Review.

Exploring the Implication of DDX3X in DENV Infection:

Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.

Brai A, Boccuto A, Monti M, Marchi S, Vicenti I, Saladini F, Trivisani CI, Pollutri A, Trombetta CM, Montomoli E, Riva V, Garbelli A, Nola EM, Zazzi M, Maga G, Dreassi E, Botta M. ACS Med Chem Lett. 2020 Apr 9;11(5):956-962. doi: 10.1021/acsmmedchemlett.9b00681. eCollection 2020 May 14. PMID: 32435411

Evaluation of Varicella Immunity during Pregnancy in Apulia Region, Southern Italy.

Trombetta CM, Montomoli E, Viviani S, Coluccio R, Marchi S.
Vaccines (Basel). 2020 May 10;8(2):214. doi: 10.3390/vaccines8020214. PMID: 32397576

Elimination of congenital rubella: a seroprevalence study of pregnant women and women of childbearing age in Italy.

Marchi S, Viviani S, Montomoli E, Trombetta CM. Hum Vaccin Immunother. 2020 Apr 2;16(4):895-898. doi: 10.1080/21645515.2019.1688041. Epub 2019 Nov 26. PMID: 31674859

Toxoplasma gondii in women of childbearing age and during pregnancy: seroprevalence study in Central and Southern Italy from 2013 to 2017.

Fanigliulo D, Marchi S, Montomoli E, Trombetta CM. Parasite. 2020;27:2. doi: 10.1051/parasite/2019080. Epub 2020 Jan 14. PMID: 31934847

hMPV

Design and validation of a semi-quantitative microneutralization assay for human Metapneumovirus A1 and B1 subtypes.

Riolo G, Biagini V, Guerrini N, Roscia G, Antonelli R, Giglioli G, Stincarelli MA, Piu P, Bonifazi C, De Grazia S, Pizzo M, Lovreglio P, Stufano A, Trombetta CM, Manenti A, Montomoli E, Dapporto F.
Sci Rep. 2025 Apr 4;15(1):11614. doi: 10.1038/s41598-025-96567-6. PMID: 40185841; PMCID: PMC11971440.



VISMEDERI SRL Headquarter

Via Franco Ferrini 53

Loc. Tognazza

53035 Monteriggioni (Siena) - Italy

Phone: +39 0577 152099

VISMEDERI SRL

Laboratories & Legal Headquarters

Loc. Belvedere, ing. 2 - Zona Industriale

53034 Colle Val d'Elsa

Siena - Italy

Phone: +39 0577 1870638

VISMEDERI SRL Laboratories

Strada del Petriccio e Belriguardo 35

53100 Siena - Italy

Phone: +39 0577 381253 / 55

info@vismederi.com

www.vismederi.com

